Integrative Biomarker Panel for Improved Lung Cancer Diagnosis Using Plasma microRNAs and Sputum Bacterial DNA

Area of Science:

• Oncology
• Molecular Diagnostics
• Microbiology

Background:

• Early and accurate diagnosis of lung cancer is crucial for patient outcomes.
• Current diagnostic methods have limitations in sensitivity and specificity.
• Molecular biomarkers offer potential for improved non-invasive lung cancer detection.

Purpose of the Study:

• To evaluate the diagnostic performance of integrating plasma microRNAs (miRNAs) and sputum bacterial DNA for lung cancer.
• To compare the diagnostic accuracy of individual and combined biomarker panels.
• To establish an integromic signature for enhanced lung cancer diagnosis.

Main Methods:

• Analysis of plasma miRNAs and sputum bacterial DNA using droplet digital PCR.
• Recruitment of lung cancer patients and cancer-free smoker controls.
• Validation of a multi-biomarker signature in an independent cohort.

Main Results:

• Individual plasma miRNA and sputum bacterial biomarkers showed moderate diagnostic performance (sensitivities 62-71%, specificities 61-79%).
• Panels of plasma miRNAs or sputum bacterial biomarkers improved sensitivity (79-85%) and specificity (74-82%).
• An integromic signature (2 plasma miRNAs, 3 sputum bacteria) achieved high sensitivity (87%) and specificity (89%), validated across diverse patient groups.

Conclusions:

• Combining plasma miRNA and sputum bacterial DNA biomarkers enhances lung cancer diagnostic accuracy.
• The developed integromic signature demonstrates robust diagnostic value, independent of clinical factors.
• This multi-modal biomarker approach represents a promising strategy for improved lung cancer detection.